MOTS-c Benefits: What the Mouse Data Shows and What the Human Data Does Not

MOTS-c has the tidiest mechanism story of any research peptide in the metabolic category, and that is exactly why it gets oversold. A peptide encoded in mitochondrial DNA that activates AMPK, prevents obesity in mice on a high fat diet, and doubles the treadmill time of old mice is a compelling set of facts. So is the fact that every one of those results comes from rodents or cell culture, and that the only controlled human trial of anything MOTS-c shaped missed its liver fat endpoint.

This page takes the benefits one at a time and puts each next to the study it came from, with the species and the dose. Research use only, and nothing here is a dosing recommendation. If you want the reported protocols rather than the evidence, the MOTS-c dosage page covers them.

What MOTS-c Actually Is

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is a 16 amino acid peptide encoded not in the nuclear genome, where almost every protein comes from, but inside the mitochondrial genome, in a short open reading frame tucked into the gene for the 12S ribosomal RNA. Lee and colleagues at the University of Southern California described it in Cell Metabolism in 2015 (Lee C et al., Cell Metab 2015;21:443, doi 10.1016/j.cmet.2015.02.009). It joined humanin as the second well characterised mitochondrial-derived peptide, and a handful of others have been described since.

That origin is the reason it matters. Mitochondria are normally thought of as taking orders from the nucleus. A peptide made from mitochondrial DNA that travels to other tissues and changes how they handle fuel is evidence that the traffic runs both ways, and the 2018 follow-up from the same group showed it goes further than that: under metabolic stress, MOTS-c moves into the nucleus itself and regulates nuclear genes (Kim KH et al., Cell Metab 2018;28:516, doi 10.1016/j.cmet.2018.06.008). It is a signalling molecule, not a structural part of the mitochondrion, and it is detectable in plasma in both mice and people.

The Mechanism: Folate Cycle, AICAR, AMPK

The 2015 paper worked out the pathway in cells and then confirmed the endpoints in mice. MOTS-c inhibits the folate cycle, and specifically lowers 5-methyltetrahydrofolate, the most abundant active form of folate. The folate cycle feeds de novo purine synthesis, and when that pathway is throttled an intermediate called AICAR builds up; in cells overexpressing MOTS-c it rose roughly twentyfold. AICAR is a well known AMP mimic, and its accumulation switches on AMPK, the cell's main energy sensor. AMPK is the pathway exercise activates, and the one metformin is thought to act through.

Downstream of AMPK in skeletal muscle, MOTS-c treatment raised GLUT4 expression, increased glucose uptake, and shifted fuel use toward fat oxidation. The authors identified skeletal muscle as the primary target tissue, which fits the later finding that muscle is also where exercise induces it most strongly.

The 2018 nuclear translocation work adds a second layer. In glucose restricted cells, MOTS-c relocated to the nucleus in an AMPK dependent way and bound to stress responsive transcription factors including NRF2, regulating genes carrying antioxidant response elements. Whether that nuclear activity is what matters for any whole body effect, or a lab curiosity, is not settled.

None of this is in dispute. It is careful, replicated cell and mouse biology from one of the strongest mitochondrial labs in the field. The question is what it predicts for a person, and that is where the rest of this page goes.

The Benefits, One at a Time

Each claim below is paired with the strongest study behind it. Species and dose are stated because they are the part vendor copy leaves out.

Insulin sensitivity and glucose handling

This is the founding claim and the best supported one in animals. Seven days of MOTS-c at 5 mg/kg/day, given intraperitoneally, improved glucose clearance on a tolerance test and raised the glucose infusion rate on a hyperinsulinaemic euglycaemic clamp by about 30%, with the gain located mainly in skeletal muscle. In 12 month old mice, which have measurable age related insulin resistance, the same seven day course restored sensitivity to something close to young animals. Plasma MOTS-c also fell with age in the mice as the resistance developed, which is the observation that started the ageing story.

Diet-induced obesity

Mice fed a high fat diet and given a much lower dose, 0.5 mg/kg/day for eight weeks, did not become obese, and they ate the same number of calories as the controls that did. That is a striking result, and it is a prevention result rather than a reversal one: the peptide started on day one of the diet. Nothing in these studies shows MOTS-c taking weight off an animal that was already obese, and nothing published shows it taking weight off a person. If fat loss is the goal, the weight loss peptides page covers the compounds that have actually been through weight loss trials.

Exercise capacity and the exercise mimetic label

The 2021 Nature Communications paper from the same lab is where the exercise language comes from (Reynolds JC et al., Nat Commun 2021;12:470, doi 10.1038/s41467-020-20790-0). Young mice on 15 mg/kg/day for two weeks ran longer and farther on a treadmill, on either a normal or a high fat diet. Middle aged and old mice on the same dose did too: the 22 month old animals ran twice as long and 2.16 times as far as untreated controls, and 17% of them reached the final sprint stage where none of the untreated mice did. In the young animals grip strength and maze learning did not change, so the gain was specifically in running capacity rather than general vigour.

The same paper contains the only human mechanistic data on MOTS-c. Ten sedentary healthy young men, mean age 24.5, exercised on a stationary bicycle. MOTS-c in their skeletal muscle rose 11.9-fold after exercise and stayed elevated through a four hour rest; circulating levels rose 1.6-fold during and 1.5-fold after exercise and returned to baseline within four hours. That establishes that exercise induces MOTS-c in people. It does not establish that MOTS-c induces exercise adaptations in people, which is the claim vendor copy makes.

Healthspan and lifespan

The late-life experiment is the one that gets quoted as a longevity result. Mice started on 15 mg/kg three times a week at 23.5 months, roughly the equivalent of a person in their seventies, showed better grip strength, stride length and overall physical capacity as they approached the end of life. Median lifespan trended 6.4% longer and maximum 7.0% longer, with a hazard ratio of 0.654, but the overall survival curve did not reach significance (P = 0.23), and the authors said larger cohorts would be needed. Healthspan improved; lifespan extension was a trend. The longevity peptides page puts that next to what epithalon and the others have.

Bone, muscle and the rest

A cluster of smaller studies extends the AMPK story into other tissues. MOTS-c reduced bone loss in ovariectomised mice, which is the model for post menopausal osteoporosis (Ming W et al., Biochem Biophys Res Commun 2016, doi 10.1016/j.bbrc.2016.05.135), and a related study found it protected the same animals from the metabolic dysfunction that follows oestrogen loss (Lu H et al., J Mol Med 2019). Those two papers are why the FDA nominations for MOTS-c listed osteoporosis alongside obesity. In muscle cells, MOTS-c lowered myostatin and the atrophy signalling behind it, and in people plasma MOTS-c ran inversely to plasma myostatin (Kumagai H et al., Am J Physiol Endocrinol Metab 2021;320:E680). All of it is consistent, all of it is preclinical or correlational, and the peptides for women page discusses why the ovariectomy models are interesting without being human evidence.

What the Human Data Actually Says

There are three kinds of human evidence on MOTS-c, and it helps to keep them separate.

Circulating levels. In a Chinese case control study of 40 obese children and adolescents against 57 controls, circulating MOTS-c was lower in the obese group, 473 versus 562 ng/mL, and when split by sex the difference held only in boys, where it also tracked inversely with BMI, waist, HOMA-IR and HbA1c (Du C et al., Pediatr Diabetes 2018, doi 10.1111/pedi.12685). In a Qatari cross sectional study of 225 adults, serum MOTS-c was significantly lower in type 2 diabetes and correlated negatively with age, HbA1c and glucose (Ramanjaneya M et al., Front Endocrinol 2019;10:331). A Chilean study of ten lean and ten obese adults found no difference between the groups at all, and within lean subjects higher MOTS-c went with more insulin resistance rather than less (Cataldo LR et al., J Investig Med 2018;66:1019). The direction is mostly consistent but not uniformly so, the samples are small, and none of it says what happens when you add the peptide.

Genetics. An East Asian mitochondrial DNA variant, m.1382A>C, changes the fourteenth amino acid of MOTS-c from lysine to glutamine and produces a less active peptide. In a meta analysis of 27,527 people across three cohorts, men carrying the C allele had a higher prevalence of type 2 diabetes, and in one cohort the excess was confined to the least physically active third (Zempo H et al., Aging 2021;13:1692, doi 10.18632/aging.202529). Women were unaffected, and so were female mice in the same paper. A separate study linked the same variant to more fast twitch muscle fibre and to sprint and power athletes rather than endurance ones (Kumagai H et al., BBA Gen Subj 2022). Earlier work had raised the variant as a possible contributor to Japanese longevity (Fuku N et al., Aging Cell 2015). This is the most interesting human evidence there is, because it shows that native MOTS-c activity matters for metabolic health in people. It still says nothing about injecting more of it.

The one interventional trial. CohBar developed CB4211, a modified MOTS-c analog, and ran a phase 1a/1b study (NCT03998514, completed April 2021). Phase 1a dosed 65 healthy adults in single and multiple ascending doses. Phase 1b randomised 20 obese adults with non alcoholic fatty liver disease to 25 mg once daily by subcutaneous injection or placebo for four weeks. The primary endpoint was safety, which it met. On the exploratory endpoints, ALT fell 21% on CB4211 against a 4% rise on placebo and AST fell 28% against 11%, both significant, and glucose fell 6% against no change. Liver fat by MRI fell about five percentage points in both arms with no separation, and body weight showed a trend. A four week study of 20 people is a signal, not a result, and it was a different molecule. It remains the only placebo controlled human data anywhere near this compound, and the peptide the company tested was not the one sold to researchers.

The Dose Gap Nobody Mentions

Every animal result above used between 0.5 and 15 mg per kilogram per day, injected into the peritoneum. Standard body surface area scaling divides a mouse dose by about 12.3 to get a human equivalent, which turns 5 mg/kg into roughly 0.4 mg/kg, or 28 mg a day for a 70 kg adult, and 15 mg/kg into roughly 85 mg a day. The reported human protocols run 5 to 10 mg per week, split into two or three injections, in four to eight week blocks. That is somewhere between twenty and a hundred times below the scaled mouse doses. The CB4211 trial, for what it is worth, used 25 mg a day of its analog.

The point is not that people should use more. There is no human dose finding data in either direction, and the reported figures are a vendor and forum convention rather than a derivation from anything. The point is that the mouse results cannot be read as predicting what a 5 mg weekly protocol does, because the mice were never given anything like it. The dosage page lays the reported protocols out with that caveat attached, and the reconstitution guide covers the handling.

MOTS-c Against the Alternatives

The other compounds run for the same reasons are SS-31, NAD+ and, honestly, exercise. This is how they compare on the thing that matters, which is human evidence.

The SS-31 page has the full trial record for the compound most often stacked with MOTS-c, the NAD+ page covers the delivery problem, and the peptides for energy comparison ranks the three together.

Regulatory Status, Briefly

MOTS-c is not approved for any use in humans anywhere. The FDA placed it in Category 2 of its interim bulk substances scheme in September 2023, the category for nominated substances with identified safety concerns, then removed it in April 2026 and sent it to the Pharmacy Compounding Advisory Committee, which voted 7 to 5 with two abstentions on 23 July 2026 to recommend it for the 503A compounding list, with obesity and osteoporosis as the nominated uses and against the recommendation of FDA review staff. A committee recommendation is not an approval and does not change what a research vendor can lawfully claim. The PCAC vote page has the tallies and the timeline. Separately, MOTS-c is explicitly named on the WADA prohibited list under S4.4.1, AMPK activators, so it is banned in tested sport at all times.

Key Takeaways

• MOTS-c is a 16 amino acid peptide encoded in mitochondrial DNA, described by Lee and colleagues in 2015, that signals to skeletal muscle and, under stress, to the nucleus
• Its mechanism runs through folate cycle inhibition, AICAR accumulation and AMPK activation, the same sensor exercise engages
• In mice it improved insulin sensitivity by about 30% in a week, prevented diet-induced obesity over eight weeks, and doubled the treadmill endurance of old animals
• Late-life dosing three times a week improved healthspan in mice; the lifespan extension was a trend that did not reach significance
• Human data is observational: lower levels in diabetes and obese boys, a 12-fold rise in muscle after cycling, and a mtDNA variant that links weaker MOTS-c to diabetes in sedentary men
• The only controlled human trial used the analog CB4211 for four weeks in 20 people: safe, lower ALT, AST and glucose, no separation on liver fat
• Reported human protocols sit twenty to a hundred times below the scaled mouse doses, so the mouse results do not predict what they do
• Not approved anywhere, recommended for compounding by an FDA advisory committee in July 2026, and prohibited by WADA

Frequently Asked Questions

What is MOTS-c?

MOTS-c is a 16 amino acid peptide encoded inside the mitochondrial genome, in a short open reading frame within the 12S ribosomal RNA gene. It was described by Lee and colleagues at USC in Cell Metabolism in 2015. It is one of a small set of mitochondrial-derived peptides, alongside humanin and the SHLPs, and it acts as a signalling molecule rather than as part of the electron transport chain. Its primary target tissue in mice appears to be skeletal muscle.

What are the claimed benefits of MOTS-c?

The claims in circulation are improved insulin sensitivity, protection against diet-induced obesity, better exercise capacity, healthier ageing, bone protection and fat loss. Each of those traces to a specific mouse or cell study. Insulin sensitivity, obesity prevention and running performance are the best supported in animals. Fat loss in people, longevity in people and energy in healthy adults have not been tested in any controlled human trial.

Has MOTS-c been tested in humans?

Not as a treatment. The human data on MOTS-c itself is observational: circulating levels are lower in people with type 2 diabetes and in obese boys, rise after exercise, fall with age, and a mitochondrial DNA variant that weakens the peptide is associated with higher diabetes prevalence in sedentary men. The one interventional trial used CB4211, a modified analog, in 20 obese adults with fatty liver for four weeks. It was safe, lowered ALT, AST and glucose relative to placebo, and did not separate from placebo on liver fat.

How does MOTS-c work?

In the 2015 paper it inhibited the folate cycle and the purine synthesis pathway tethered to it, which caused the AMP analog AICAR to accumulate and activated AMPK, the same energy sensor that exercise and metformin engage. AMPK activation in muscle increases glucose uptake and fat oxidation. A 2018 follow-up showed that under metabolic stress MOTS-c also moves into the nucleus and regulates stress-response genes, including those controlled by NRF2. Both findings are from cells and mice.

Is MOTS-c the same as an exercise mimetic?

It is often called one, and the label is defensible for mice: treated old mice ran twice as long on a treadmill and late-life intermittent dosing improved physical capacity and healthspan. In humans the connection runs the other way, exercise raises endogenous MOTS-c in muscle and blood. Whether injecting MOTS-c produces exercise-like adaptations in a person has not been tested.